A new study has shown that inflammatory arthritis occurring as a side effect of immune checkpoint inhibitors behaves like an immune-memory disease, suggesting that certain immune cell populations could serve as potential biomarkers for targeted therapies. The study was co-led by Roza I. Nurieva, Ph.D., professor of Immunology, Synat Keam, Ph.D., postdoctoral fellow in the Nurieva Laboratory, and Yuanteng Jeff Li, M.D., assistant professor of General Internal Medicine, along with Sang Taek Kim, M.D., Ph.D., assistant professor from Yale University. The findings showed that two specific immune cell populations were present in both initial and recurrent arthritis flares.
“Cancer immunotherapy works by creating a lasting immune response against tumors, but that same persistence may also contribute to recurring inflammatory side effects that can be debilitating for patients,” Nurieva said. “By identifying the immune cells that drive recurrent arthritis, we can inform treatment strategies that reduce the risk of future flares while preserving the therapy’s effectiveness against cancer.”